

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1858)

PRELIMINARY RESULTS FOR THE YEAR OF 2024

This announcement is made by Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively as the “**Group**”) pursuant to Rules 13.09(2) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The major financial data and indicators for the year of 2024 set forth in this announcement are only preliminary accounting data and have not been audited by an accounting firm. The specific data shall be based on the Company’s annual report for the year of 2024. Investors are advised to pay attention to the investment risks involved.

I. MAJOR FINANCIAL DATA AND INDICATORS FOR THE YEAR OF 2024 (CONSOLIDATED AND UNAUDITED)

Unit: RMB

Items	Current Reporting Period	Corresponding Period of Last Year	Rate of Increase/Decrease (%)
Total operating revenue	805,857,022.19	1,208,523,845.88	-33.32
Operating profit	130,711,152.28	305,975,463.53	-57.28
Gross profit	131,595,627.39	305,905,863.04	-56.98
Net profit attributable to owners of the parent company	124,984,999.16	277,824,014.12	-55.01
Net profit attributable to owners of the parent company after deducting non-recurring profit or loss	94,532,991.97	254,128,319.48	-62.80
Basic earnings per share (RMB/share)	0.33	0.72	-54.17
Weighted average return on net assets (%)	4.37	9.93	Decrease by 5.56 percentage points

	End of the Current Reporting Period	Beginning of the Current Reporting Period	Rate of Increase/ Decrease (%)
Total assets	3,465,735,514.23	3,649,560,924.88	-5.04
Owner's equity attributable to the parent company	2,819,899,272.85	2,877,466,853.34	-2.00
Share capital	383,568,500.00	383,568,500.00	—
Net assets per share attributable to owners of the parent company (RMB/share)	7.35	7.50	-2.00

- Notes: 1. The data for the beginning of the current reporting period is the same as the data for the end of last year as required to be disclosed by law.
2. All amounts in this announcement are rounded to 2 decimal places unless otherwise indicated. Any discrepancy is due to rounding.
3. The above financial data and indicators are set out based on those data in the consolidated statements, but they have not been audited. The final data shall be based on those data in the 2024 annual report of the Company.

II. EXPLANATION OF THE OPERATING RESULTS AND FINANCIAL POSITION

(I) Operating Conditions, Financial Position and Major Factors Affecting Operating Results During the Reporting Period.

During the reporting period, the centralized procurement policy continued to deepen, and the Company actively implemented the national centralized volume-based procurement policy, resulting in a decrease in the prices and profit of the relevant products, which had an impact on the Company's results.

The total operating revenue of the Company amounted to RMB805,857,022.19, representing a decrease of 33.32% over the same period of last year; the net profit attributable to owners of the parent company amounted to RMB124,984,999.16, representing a decrease of 55.01% over the same period of last year.

At the end of the reporting period, total assets of the Company amounted to RMB3,465,735,514.23, representing a decrease of 5.04% over the beginning of the period; the owners' equity attributable to the parent company amounted to RMB2,819,899,272.85, representing a decrease of 2.00% over the beginning of the period; and the net assets per share attributable to owners of the parent company amounted to RMB7.35, representing a decrease of 2.00% over the beginning of the period.

(II) Main Reasons for the Increase/Decrease of 30% or more of the Relevant Items in the above Table.

During the reporting period, the total operating revenue of the Company amounted to RMB805,857,022.19, representing a decrease of 33.32% over the same period of last year, which was mainly due to the Company actively implemented the national centralized volume-based procurement policy and won the bidding for all joint products in the continuous procurement after the expiration of the state-organized centralized volume-based procurement agreement of artificial joints. In the state-organized centralized volume-based procurement of intraocular lens and sports medicine consumables, all the sports medicine products of the Company won the bidding, and the prices of the Company's related products decreased and revenue declined.

During the reporting period, the operating profit of the Company amounted to RMB130,711,152.28, representing a decrease of 57.28% over the same period of last year; the gross profit amounted to RMB131,595,627.39, representing a decrease of 56.98% over the same period of last year; the net profit attributable to owners of the parent company amounted to RMB124,984,999.16, representing a decrease of 55.01%

over the same period of last year; and the net profit attributable to owners of the parent company after deducting non-recurring profit or loss amounted to RMB94,532,991.97, representing a decrease of 62.80% over the same period of last year, which was mainly attributable to the continuous deepening of the centralized procurement policy, the Company actively implemented the national centralized volume-based procurement policy, the prices of the relevant products decreased and the revenue decreased. In order to cope with the changing industry policies and ensure the stable supply of products that won the bidding in centralized procurement, the Company adjusted the prices of channel inventory before the implementation of centralized procurement, resulting in the decrease of the Company's net profit.

During the reporting period, the basic earnings per share of the Company amounted to RMB0.33, representing a decrease of 54.17% over the same period of last year, which was mainly due to the decrease in basic earnings per share as a result of the decrease in profit for the reporting period.

III. RISK WARNING

There are no significant uncertainties affecting the accuracy of the preliminary results. However, the major financial data for the year of 2024 set forth in this announcement is preliminary accounting data and has not been audited by an accounting firm. The specific and accurate financial data shall be based on those data in the audited 2024 annual report to be formally disclosed by the Company. Investors are advised to pay attention to the investment risks involved.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Chairman
Shi Wenling

Beijing, the PRC, 27 February 2025

As at the date of this announcement, the executive Directors are Ms. Shi Wenling, Mr. Shi Chunbao, Ms. Yue Shujun and Mr. Xie Feng Bao; the non-executive Director is Mr. Wang Xin; and the independent non-executive Directors are Ms. Xu Hong, Mr. Weng Jie and Mr. Wong Tak Shing.

* For identification purposes only